Curis Inc (CRIS) 2.88 $CRIS Curis Presents Preclinical

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 9:53 PM

Curis Inc (CRIS) 2.88 $CRIS

Curis Presents Preclinical Data on CUDC-427 at AACR Annual Meeting
GlobeNewswire - Wed Apr 22, 7:15AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, announced today data presented from in vitro and in vivo studies for CUDC-427, an antagonist of inhibitor of apoptosis (IAP) proteins, at the American Association for Cancer Research (AACR) 2015 Annual Meeting. CUDC-427 is being studied in a Phase 1 trial in patients with advanced solid tumors or lymphoma. Curis' collaborator, Aurigene Discovery Technologies Limited, also reported preclinical data on its interleukin-1 receptor association kinase-4 (IRAK-4) inhibitor program at AACR.
CRIS: 2.88 (+0.09), RDY: 56.58 (+0.30)

Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015
PR Newswire - Sat Apr 18, 7:00AM CDT
Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be presenting data at the poster sessions from two programs at the American Associate of Cancer Research Annual Meeting (April 18-22 in Philadelphia, PA).
CRIS: 2.88 (+0.09)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 4:36PM CDT

MNK: 122.95 (-2.22), FARO: 44.64 (-0.93), MDVN: 128.88 (+0.29), CRIS: 2.88 (+0.09), E: 36.62 (+0.43), PH: 123.47 (+1.33), YOKU: 16.42 (-0.21), FXCM: 2.13 (+0.02), VSLR: 14.33 (+0.36), IGT: 19.88 (-0.02)

Biotech Stocks Technical Report -- Novavax, MannKind, Juno Therapeutics, Curis, and Ohr Pharma
PR Newswire - Thu Apr 16, 8:15AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.88 (+0.09), NVAX: 8.51 (+0.09), OHRP: 2.72 (+0.08), JUNO: 55.72 (-0.68), MNKD: 4.90 (-0.09)

Curis Announces Presentation of Data From CUDC-427 and IRAK-4 Programs at AACR Annual Meeting
GlobeNewswire - Tue Apr 14, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Curis scientists and its collaborator, Aurigene Discovery Technologies Limited, will present data from two programs at the Annual Meeting of American Association of Cancer Research (AACR) to be held April 18 - 22, 2015 in Philadelphia.
CRIS: 2.88 (+0.09), RDY: 56.58 (+0.30)

Curis' CUDC-907 an Orphan Drug for blood cancer
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 9:01AM CDT

CRIS: 2.88 (+0.09)

Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 8:18AM CDT

RESN: 3.77 (-0.06), HLF: 46.63 (-0.13), MHR: 2.34 (-0.07), NG: 3.56 (-0.07), CRIS: 2.88 (+0.09), GBSN: 4.98 (+1.44), QURE: 26.15 (-1.44), CYTX: 0.96 (-0.09), GAME: 6.85 (unch), BIND: 7.01 (-0.30), DGLY: 13.13 (+0.08), CAPN: 6.99 (-0.29)

Curis Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Mon Apr 06, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead proprietary drug candidate, CUDC-907 for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL).
CRIS: 2.88 (+0.09)

Roth Capital Weighs In On 5 Biotech Stocks To Watch
TipRanks - at Seeking Alpha - Mon Apr 06, 4:02AM CDT
By Sarah Roden As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to "focus on names with definitive catalysts." Though the analyst rates 15 biotech stocks,...
CRIS: 2.88 (+0.09), GNVC: 2.86 (-0.11), CLDX: 28.95 (+1.08), BLRX: 2.12 (unch), KERX: 11.52 (-0.15)

Coverage of Biotech Equities -- MannKind, Novavax, Curis, Pharmacyclics, and Alexion Pharma
PR Newswire - Tue Mar 10, 8:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.88 (+0.09), PCYC: 256.98 (-0.77), NVAX: 8.51 (+0.09), ALXN: 188.19 (+1.41), MNKD: 4.90 (-0.09)

Curis closes equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:18PM CST

CRIS: 2.88 (+0.09)

Curis Announces Closing of Public Offering of Common Stock
GlobeNewswire - Mon Mar 02, 3:00PM CST
Curis, Inc. (Nasdaq:CRIS), announced today the closing of its previously announced public offering of common stock. Curis sold 25,090,908 shares of its common stock in the offering at a price to the public of $2.75 per share, including the exercise in full by the underwriters of their option to purchase an additional 3,272,727 shares of common stock at the public offering price. Curis received net proceeds of approximately $64.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.
CRIS: 2.88 (+0.09)

Curis prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:54AM CST

CRIS: 2.88 (+0.09)

Curis reports 4Q loss
Automated Insights - Tue Feb 24, 4:31PM CST
LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $5.7 million in its fourth quarter.
CRIS: 2.88 (+0.09)

Curis initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 4:05PM CST

CRIS: 2.88 (+0.09)

Curis EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 3:56PM CST

CRIS: 2.88 (+0.09)

A Look at the Latest Occurrences in the Biotechnology Sector: Special Research on China Biologic Products, Compugen, Curis, CytRx, and DBV Technologies
PR Newswire - Mon Feb 16, 7:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
CBPO: 99.67 (-0.84), CRIS: 2.88 (+0.09), DBVT: 25.66 (-0.01), CYTR: 5.21 (-0.06), CGEN: 7.10 (+0.01)

Strength Seen in Curis (CRIS): Stock Moves 9.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:25AM CST
Curis (CRIS) was a big mover last session, with shares rising over 9% on the day.
CRIS: 2.88 (+0.09), AFFX: 12.57 (-0.13)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Geron Corp Faces Fiduciary Duty Investigation

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

AI and Storytelling Make Waves in Science Education

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...